Novel immunosuppressants in asthma

Chemical Immunology

Volumn 78, Issue , 2000, Pages 124-134

  Kon, O M ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CORTICOSTEROID; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GOLD; HYBRID PROTEIN; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID; OKT 4; PLACEBO; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; TERIFLUNOMIDE; ANTIRHEUMATIC AGENT; CD4 ANTIGEN; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; ORGANOGOLD COMPOUND;

ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BLOOD DISEASE; CELL FUNCTION; CLINICAL TRIAL; CORTICOSTEROID THERAPY; CROSSOVER PROCEDURE; DIARRHEA; GINGIVA HYPERPLASIA; HUMAN; HYPERTRICHOSIS; IMMUNOSUPPRESSIVE TREATMENT; LIVER DYSFUNCTION; LIVER FIBROSIS; MOUTH ULCER; PARESTHESIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINURIA; RASH; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; TREMOR; BIOLOGICAL MODEL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; IMMUNOLOGY; RANDOMIZED CONTROLLED TRIAL;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; ANTIRHEUMATIC AGENTS; ASTHMA; CROSS-OVER STUDIES; CYCLOSPORINE; DOUBLE-BLIND METHOD; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; MODELS, IMMUNOLOGICAL; ORGANOGOLD COMPOUNDS; RANDOMIZED CONTROLLED TRIALS; SIROLIMUS; TACROLIMUS;

EID: 0033794944     PISSN: 10150145     EISSN: None     Source Type: Journal    
DOI: 10.1159/000058822     Document Type: Review

References (57)

1. The mechanism of action of methotrexate in rheumatoid arthritis: The search continues
2. 4 and complement C5a
3. The effect of methotrexate and hydroxyurea on neutrophil chemotaxis
4. Methotrexate inhibits the human C5a-induced skin response in patients with psoriasis
5. Inhibition of basophil histamine release by methotrexate
6. Studies on the effect of methotrexate on macrophage function
7. Methotrexate: Mechanism of action in rheumatoid arthritis
8. Cell-type specific response of peripheral blood lymphocytes to methotrexate in the treatment of rheumatoid arthritis
9. Methotrexate in the treatment of corticosteroid-dependent asthma. A double-blind crossover study
10. Randomised, double-blind, placebo-controlled trial of methotrexate in steroid-dependent asthma
11. Methotrexate in the treatment of steroid-dependent asthma
12. Ccmparison of oral pulse methotrexate with placebo in the treatment of severe glucocorticosteroid-dependent asthma
13. Controlled trial of methotrexate in patients with severe chronic asthma
14. The role of methotrexate in the management of steroid-dependent asthma
15. Comparison of methotrexate 30 mg per week with placebo in chronic steroid-dependent asthma: A 12-week double-blind, cross-over study
16. Methotrexate in the management of severe steroid-dependent asthma
17. Lack of benefit of methotrexate in severe, steroid-dependent asthma. A double-blind, placebo-controlled study
18. Is methotrexate effective as a steroid-sparing agent in steroid-dependent asthmatics? A meta-analysis
19. Low-dose methotrexate spares steroid usage in steroid-dependent asthmatic patients: A meta-analysis
20. Methotrexate-induced chronic liver injury: Guidelines for detection and prevention. The ACG Committee on FDA-Related Matters. American College of Gastroenterology
21. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology
22. Opportunistic infection during treatment with low-dose methotrexate
23. Pneumocystis carinii pneumonia complicating low-dose methotrexate treatment for rheumatoid arthritis
24. Pneumocystis carinii pneumonia as a complication of methotrexate treatment of asthma
25. Fatal pneumocystis pneumonia in asthmatic patient treated with methotrexate
26. Fatal chickenpox pneumonia in an asthmatic patient on oral steroids and methotrexate
27. Fatal varicella zoster infection in a severe steroid-dependent asthmatic patient receiving methotrexate
28. Methotrexate-induced asthma
29. Methotrexate: Does it treat or induce asthma?
30. Methotrexate pneumonitis in bronchial asthma
31. Modulation of the release of histamine and arachidonic acid metabolites from human basophils and mast cells by auranofin
32. Auranofin modulates mast cell histamine and polymorphonuclear leukocyte collagenase release
33. Inhibition by auranofin of pharmacologic and antigen-induced contractions of the isolated guinea pig trachea
34. 2 production by polymorphonuclear leukocytes
35. Effects of auranofin on leukotriene production and leukotriene-stimulated neutrophil function
36. Gold sodium thiomalate selectivity inhibits interleukin-5-mediated eosinophil survival
37. Gold salt in the treatment of bronchial asthma - A double-blind study
38. Chrysotherapy in the treatment of corticosteroid-dependent asthma
39. Auranofin in the treatment of steroid dependent asthma: A double-blind study
40. A placebo-controlled multicenter study of auranofin in the treatment of patients with corticosteroid-dependent asthma. Auranofin Multicenter Drug Trial
41. Cyclosporine
42. IL-5 production by CD4+ T cells of asthmatic patients is suppressed by glucocorticoids and the immunosuppressants FK506 and cyclosporin A
43. FK506 and cyclosporin A inhibit granulocyte/macrophage colony-stimulating factor production by mononuclear cells in asthma
44. Trial of cyclosporin in corticosteroid-dependent chronic severe asthma
45. Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma
46. Treatment of steroid-dependent bronchial asthma with cyclosporin
47. Cyclosporine A reduces T lymphocyte activity and improves airway hyperresponsiveness in corticosteroid-dependent chronic severe asthma
48. Effect of cyclosporin A on the allergen-induced late asthmatic reaction
49. Delivery and distribution of aerosolized cyclosporine in lung allograft recipients
50. Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma
51. Clinical trial of tacrolimus versus cyclosporine in lung transplantation
52. Effects of rapamycin, cyclosporin A, and dexamethasone on interleukin-5-induced eosinophil degranulation and prolonged survival
53. Mechanism of action of leflunomide in rheumatoid arthritis
54. Leflunomide, a novel immunomodulating agent, prevents the development of allergic sensitization in an animal model of allergic asthma
55. Update on preclinical and clinical experience with mycophenolate mofetil
56. Preventing allograft rejection with CTLA4IG: Effect of donor-specific transfusion route or timing